Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/9112
Title: The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?
Authors: Alkis, O.
Zümrütbaş, Ali Ersin
Toktas, C.
Aybek, Hülya
Aybek, Zafer
Keywords: biomarkers
brain derived neurotrophic factor
glycosaminoglycans
monocyte chemoattractant protein 1
nerve growth factor
overactive bladder
cre recombinase
Gag protein
monocyte chemotactic protein 1
solifenacin
biological marker
CCL2 protein, human
urinary tract agent
adult
Article
clinical article
controlled study
disease marker
disease severity
female
human
male
outcome assessment
postmenopause
prediction
premenopause
questionnaire
symptom
treatment duration
treatment response
urine sampling
validation study
aged
middle aged
treatment failure
treatment outcome
urine
Adult
Aged
Biomarkers
Brain-Derived Neurotrophic Factor
Chemokine CCL2
Female
Humans
Male
Middle Aged
Nerve Growth Factor
Solifenacin Succinate
Treatment Failure
Treatment Outcome
Urinary Bladder, Overactive
Urological Agents
Publisher: John Wiley and Sons Inc.
Abstract: Aims: The main objective of this study was to define urinary biomarkers that can predict the severity of overactive bladder and detect patients who would benefit most from treatment. Methods: Patients with an OAB diagnosis and healthy controls were included in the study. A bladder diary and a validated OAB questionnaire were given to all patients. In the OAB group, solifenacin 5 mg daily was given for 1 month. Urine samples were taken before the treatment and after the first month of the treatment in both groups and urinary BDNF, NGF, GAG, and MCP-1 levels were measured. Results: A total of 45 OAB patients and 45 healthy age-matched controls were included. BDNF/Cre, NGF/Cre, MCP-1/Cre, and GAG/Cre levels were significantly higher in the OAB group. The levels of these biomarkers significantly decreased after 1 month of solifenacin treatment. After treatment, 66.7% of patients OAB symptoms were relieved and 33.3% did not respond to the treatment. Although basal biomarker levels did not differ between responder and non-responder groups, the ratio of decrease in biomarker levels was significantly higher in treatment-sensitive patients. Postmenopausal women were more resistant to treatment when compared with the premenopausal group. Conclusions: Urinary biomarkers have a role in the pathophysiology of OAB however they did not predict the patients who would benefit from the treatment and in whom antimuscarinics would be useless. Future studies with higher numbers of patients and different OAB subgroups are needed to investigate the exact role of these (and other) biomarkers. Neurourol. Urodynam. 36:390–393, 2017. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
URI: https://hdl.handle.net/11499/9112
https://doi.org/10.1002/nau.22939
ISSN: 0733-2467
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

28
checked on Dec 14, 2024

WEB OF SCIENCETM
Citations

28
checked on Dec 18, 2024

Page view(s)

44
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.